about
Depressogenic effects of medications: a reviewEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewAltered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressantsNon-vision adverse events with vigabatrin therapy.Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.Suicide risk in people with epilepsy taking antiepileptic drugs.Antidepressant drugs: indications and guidelines for use in epilepsy.When is it inappropriate to prescribe psychotropic medication?Negative effects of antiepileptic drugs on mood in patients with epilepsy.The use of newer anticonvulsants in neuropsychiatric disorders.Complex partial seizures and depression.Behavioural effects of the newer antiepileptic drugs: an update.Role of valproate across the ages. Treatment of epilepsy in adults.Effects of antiepileptic drugs on mood and behavior.Assessing the role of drugs in suicidal ideation and suicidality.Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)Vigabatrin: 2008 update.Treatment of refractory complex partial seizures: role of vigabatrin.Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.Suicidality in epilepsy and possible effects of antiepileptic drugs.Treatment of epilepsy in children with developmental disabilities.Advances in pharmacotherapy for pediatric anxiety disorders.GABAergic drugs in the treatment of epilepsy: modern or outmoded?Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications.Vigabatrin therapy for refractory complex partial seizures: review of major European trials.Balancing clinical benefits of vigabatrin with its associated risk of vision loss.Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology.Treatment of pediatric anxiety disorders.The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.The comorbidity of epilepsy and depression: diagnosis and treatment.Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence.Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?Depression and mental health help-seeking behaviors in a predominantly African American population of children and adolescents with epilepsy.
P2860
Q24635465-9C03D1A6-3EEC-4B78-86CB-149BF86E0F46Q26743786-6FE22D0D-B2FD-49E0-95C0-7F3D75CB1553Q30887852-AB194101-B34B-4B9D-A981-CA6C507FA316Q34068916-1A733777-0B52-4649-BC06-93F2E755B240Q34186198-3627387D-61C2-4CEC-8A73-3A1E371FB641Q34350056-7EFED347-EF66-4910-A7BF-076A11C1E19BQ34570588-A15D4B15-8C86-4CF0-A611-279EFDC84FADQ34570618-47AB56B7-5DE6-498C-B079-E6F79A67A939Q34580773-720D5D2F-4DA7-49A1-80E8-353FAAD782FAQ34856249-F1BFBB6D-DD65-4496-B2BE-B02156778AEFQ35294831-ADF447B3-4CFD-4C59-A71F-EA8FC775F7EDQ35609738-F4EBB366-7717-4CAE-B039-69ED44BD1C0FQ36507535-79EE76E3-B5E3-40BA-86A0-901006EF8B99Q36653769-9D30BC1E-CF89-4DEA-B6FC-9AC2ADD668C5Q36830144-7C93886F-EA43-4F0C-87D3-4B52FC3AE65EQ37242260-BC5D6E09-AAF4-45A8-8472-C265AE535A49Q37397004-26FEFCE7-43B3-4AEA-A4BD-3D26E4FE1688Q37620193-DBD233ED-25A7-401D-8527-F7FDCD279454Q37642768-2C32CA3C-E9FA-4623-8426-93548405F218Q37754086-3219BEBA-0783-45F2-931A-4824212DA28CQ37803574-2BF4F883-E106-464B-958D-CF822F5A1884Q37827822-609AAAC8-DAB8-4723-B248-D82DE71D14EAQ37856281-8D1B4776-CEA7-4999-B95C-20B11635D498Q37880900-88E957F0-5766-42F1-BC67-080BCEA634CFQ37953576-5D34E447-4411-4E13-8F5D-25BB9D87BACDQ37953583-5F09551D-40C3-46B3-9DED-EDB9CE884AB0Q38045012-1F3C7555-BD5C-4F72-8CB5-DDF73FBEDBAEQ38166460-4248346A-C0A8-4869-98F2-9A0DECAEBDB9Q38621010-3858155B-07DF-4F01-959E-E315932541CAQ38872053-AC740B43-1E9F-4503-8A68-AC0BDB9FFB4BQ39094490-56191EE8-A9FA-43D8-8EB2-46C2AC3E36CFQ42792453-F4B89193-AEC4-4CBE-B5AF-AF490BC07005Q43272828-EB5C7565-6539-4C3A-ADB2-BE711277A254Q46099781-49A7CEC4-70FD-413B-BDFB-0485B33044B3Q46318966-868E53C5-E544-48B8-9989-A83073D43A04
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Psychiatric adverse events during vigabatrin therapy
@ast
Psychiatric adverse events during vigabatrin therapy
@en
Psychiatric adverse events during vigabatrin therapy
@nl
type
label
Psychiatric adverse events during vigabatrin therapy
@ast
Psychiatric adverse events during vigabatrin therapy
@en
Psychiatric adverse events during vigabatrin therapy
@nl
prefLabel
Psychiatric adverse events during vigabatrin therapy
@ast
Psychiatric adverse events during vigabatrin therapy
@en
Psychiatric adverse events during vigabatrin therapy
@nl
P3181
P356
P1433
P1476
Psychiatric adverse events during vigabatrin therapy
@en
P2093
D F Levinson
P304
P3181
P356
10.1212/WNL.53.7.1503
P407
P577
1999-10-01T00:00:00Z